Search

Search Constraints

You searched for: Author/Creator Untch, Michael

Search Results

1. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Issue 10075 (25th March 2017)

2. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Issue 4 (April 2018)

3. Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. (5th June 2018)

4. Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience. (28th January 2013)

5. Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials. (July 2021)

6. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Issue 8 (August 2021)

7. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". (February 2021)

8. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. Issue 2 (16th November 2020)

9. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. Issue 2 (16th November 2020)

10. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. Issue 2 (16th November 2020)